EditorialKommentar
Federal Trade Commission Oversight of the Pharmaceutical Industry
JAMA · 2024
DOI: 10.1001/jama.2024.1509 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA, 2024. Verfasst von Amy Kapczynski Jd. Beteiligte Einrichtung: Yale Law School, New Haven, Connecticut. Hauptthemen laut MEDLINE: Drug Industry, United States Federal Trade Commission, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
C. Joseph Ross Daval, JD; Alexander C. Egilman, BA; Ameet Sarpatwari, PhD, JD; Aaron S. Kesselheim, MD, JD, MPH
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Drug IndustryUnited States Federal Trade CommissionDrug CostsHumansGovernment RegulationUnited StatesUnited States Food and Drug Administration
Autor:innen und Institutionen
- Yale Law School, New Haven, Connecticut.
Zitieren
APA
Kapczynski Jd, A. (2024). Federal Trade Commission Oversight of the Pharmaceutical Industry. JAMA. https://doi.org/10.1001/jama.2024.1509
Vancouver
Kapczynski Jd A. Federal Trade Commission Oversight of the Pharmaceutical Industry. JAMA. 2024. doi:10.1001/jama.2024.1509
BibTeX
@article{KapczynskiJd2024,
author = {Kapczynski Jd, Amy},
title = {Federal Trade Commission Oversight of the Pharmaceutical Industry},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.1509}
}
EUVIMED